Difference between revisions of "Part:BBa K2918001"
Hafsaflats (Talk | contribs) |
Weronika77 (Talk | contribs) (→Usage and Biology) |
||
(49 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
− | |||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K2918001 short</partinfo> | <partinfo>BBa_K2918001 short</partinfo> | ||
− | Terminal Protein of the Φ29 bacteriophage | + | Terminal Protein of the Φ29 bacteriophage |
− | = | + | <span class='h3bb'>Sequence and Features</span> |
+ | <partinfo>BBa_K2918001 SequenceAndFeatures</partinfo> | ||
+ | The part has been confirmed by sequencing and there are no mutations. | ||
− | The replication of DNA | + | ===Usage and Biology=== |
+ | |||
+ | The Φ29 replication mechanism involves replication of a protein-primed based replication linear DNA. Protein primed replication, unlike the conventional DNA or RNA primed mechanism, does not depend on specific sequences of DNA/RNA which simplifies the design of replication systems. The Φ29 replication can be established by using four simple proteins: Φ29 DNA polymerase <html><a href="https://parts.igem.org/Part:BBa_K2918034">(DNAP/p2)</a></html>, terminal protein <html><a href="https://parts.igem.org/Part:BBa_K2918001">(TP/p3)</a></html>, single stranded binding protein <html><a href="https://parts.igem.org/Part:BBa_K2918002"> (SSB/p5)</a></html> and double stranded binding protein <html><a href="https://parts.igem.org/Part:BBa_K2918003">(DSB/p6)</a></html>. The replication process begins by binding of the Φ29 DNA polymerase and terminal protein complex at the origins of replication (<html><a href="https://parts.igem.org/Part:BBa_K2918033">OriL</a></html> and <html><a href="https://parts.igem.org/Part:BBa_K2918061">OriR</a></html>), which flank the protein-primed linear plasmid <html><a href="#Salas1994">(Salas et al., 1994)</a></html>. The double stranded DNA binding proteins aid in the process of replication and bind more intensely at the origins of replication (OriL and OriR), destabilizing the region and facilitating strand displacement. Single stranded binding proteins bind to the displaced DNA strand preventing strand switching of the DNA polymerase and protecting the linear plasmid from host nucleases <html><a href="#Salas1994">(Salas et al., 1994)</a></html>. The replication mechanism is depicted in Figure 1. If you want to read more about this mechanism, you can take a look at our <html><a target="_blank" href="http://2019.igem.org/Team:TUDelft/Design#orthorep">Design</a></html> page! | ||
+ | |||
+ | <div><ul> | ||
+ | <center> | ||
+ | <li style="display: inline-block;"> [[File:T--TUDelft--replicationpartstest.jpg|thumb|none|550px|<b>Figure 1:</b> Overview of phi29 replication mechanism]] </li> | ||
+ | </center> | ||
+ | </ul></div> | ||
+ | |||
+ | The Φ29 replication system is promising in many ways: | ||
+ | <ul> | ||
+ | <li>The Φ29 DNA polymerase has the highest processivity of all known single subunit DNA polymerases <html><a href="#Blanco1988">(Blanco et al., 1989)</a></html>, and can be used for whole genome amplification. </li> | ||
+ | <li>The Φ29 machinery along with cell-free expression systems can be used to establish the three dogmas of biology <I>in vitro</I>, setting the basis for artificial cell development. </li> | ||
+ | <li>The existing DNA-protein covalent bonds offer many possibilities to engineer the terminal proteins with functional peptide | ||
+ | sequences. </li> | ||
+ | <li>We envision that the unique configuration of the double-stranded, protein-capped linear replicon will be a basis for many | ||
+ | new engineered protein-DNA complexes.</li> | ||
+ | <li>Orthogonal replication enables not only replication independent from the host, but also the ability to engineer the orthogonal | ||
+ | DNA polymerase’s fidelity without introducing mutations in the cell’s genome which makes <I>in vivo</I> directed evolution a | ||
+ | possibility. </li></ul> | ||
+ | |||
+ | ===Characterization=== | ||
+ | For expressing our phi29 TP we used PURE<I>frex</I> 2.0. This is an <I>E. coli</I> based cell-free protein synthesis system and it contains all the elements to make <I>in vitro</I> translation-transcription possible. A 10-μL reaction consists of 5 μL feeding buffer, 0.5 μL enzyme solution, 1 μL ribosome solution, 5 nM DNA and RNAse-free milliQ for filling up the volume. For fluorescent labeling, 0.5 μL of BODIPY-Lys-tRNA<sub>Lys</sub> (FluoroTectTM GreenLys, Promega) was added, this binds to the translation products at the lysine residues sites.The proteins were identified by mass spectrometry. From the 10-μL reaction, 2 μL was analyzed by the mass spectrometer. | ||
+ | |||
+ | <b>Mass Spectrometer</b><br> | ||
+ | Mass spectrometry was used to confirm the identity of the proteins. The mass spectrometer looks for the mass of unique peptide sequences, and their elution time. For TP these unique peptide sequences are: <I>IAEIER</I>, <I>LVDEK</I> and <I>ILSYLEQYR</I>. Data was normalized to the presence of the elongation factor EF-TU, which can be found in the same concentration in all PURE system reactions. The optimized parameters and raw data for the mass spectrometry method can be found [[Media:T--TUDelft--transitionlist.xls.zip|here]] and [[Media:T--TUDelft--RAWDATA.xlsx.zip|here]]. | ||
+ | |||
+ | <div><ul> | ||
+ | <li style="display: inline-block;"> [[File:T--TUDelft--TP1.png|thumb|none|280px|<b>Figure 2A:</b> Identification by mass spectrometry of IAEIER peptide]] </li> | ||
+ | <li style="display: inline-block;"> [[File:T--TUDelft--TP2.png|thumb|none|280px|<b>Figure 2B:</b> Identification in mass spectrometry of LVDEK peptide]] </li> | ||
+ | <li style="display: inline-block;"> [[File:T--TUDelft--TP3.png|thumb|none|280px|<b>Figure 2C:</b> Identification in mass spectrometry of ILSYLEQYR peptide]] </li> | ||
+ | </ul></div> | ||
+ | |||
+ | The intensity of the mass spectrographs shown in Figure 2 only reflect the <I>occurrence</I> of a given sequence in the sample. The successful expression of DNAP from our construct was confirmed by mass spectrometry as reported by figure 2. In conclusion, the results were positive and the identity of the proteins could be further by mass spectrometry. | ||
+ | |||
+ | ===Toxicity=== | ||
+ | |||
+ | Our Sci-Phi 29 tool is based on four components of the Φ29 bacteriophage: DNAP, TP, p5 and p6. However, overexpression of these proteins are toxic for the cell. In order to determine the optimal expression levels of the proteins in live cells, we carried out viability assays in <i>E. coli</i> BL21(DE3) pLysS. The results are shown in the graphs below. | ||
+ | |||
+ | <div><ul> | ||
+ | <li style="display: inline-block;"> [[File:T--TUDelft--TPnoiptg.png|thumb|none|444px|<b>Figure 3A:</b> The highest growth rate of phi29 TP under different promoter strengths (weak, medium, Wild-Type) with no IPTG induction]] </li> | ||
+ | <li style="display: inline-block;"> [[File:T--TUDelft--tp1iptg.png|thumb|none|444px|<b>Figure 3B:</b> The highest growth rate of phi29 TP under different promoter strengths (weak, medium, Wild-Type) with 1 mM IPTG induction]] </li> | ||
+ | <li style="display: inline-block;"> [[File:T--TUDelft--tp10iptg.png|thumb|none|444px|<b>Figure 3C:</b> The highest growth rate of phi29 TP under different promoter strengths (weak, medium, Wild-Type) with 10 mM IPTG induction]] </li> | ||
+ | </ul></div> | ||
===Strain Construction=== | ===Strain Construction=== | ||
+ | The DNA sequence of the part was synthesized by IDT with flanking BpiI sites and respective MoClo compatible coding sequence overhangs. The part was then cloned in a level 0 MoClo backbone <html><a href="http://www.addgene.org/47998/"> pICH41308 </a></html> and the sequence was confirmed by sequencing. The cloning protocol can be found in the MoClo section below. | ||
+ | ===Modular Cloning=== | ||
+ | Modular Cloning (MoClo) is a system which allows for efficient one pot assembly of multiple DNA fragments. The MoClo system consists of Type IIS restriction enzymes that cleave DNA 4 to 8 base pairs away from the recognition sites. Cleavage outside of the recognition site allows for customization of the overhangs generated. The MoClo system is hierarchical. First, basic parts (promoters, UTRs, CDS and terminators) are assembled in level 0 plasmids in the kit. In a single reaction, the individual parts can be assembled into vectors containing transcriptional units (level 1). Furthermore, MoClo allows for directional assembly of multiple transcriptional units. Successful assembly of constructs using MoClo can be confirmed by visual readouts (blue/white or red/white screening). | ||
+ | For the protocol, you can find it <html><a href="http://2019.igem.org/Team:TUDelft/Experiments" target="_blank">here</a>.</html> | ||
+ | |||
+ | |||
+ | <b>Note: The basic parts sequences of the Sci-Phi 29 collection in the registry contain only the part sequence and therefore contain no overhangs or restriction sites. For synthesizing MoClo compatible parts, refer to table 2. </b> | ||
+ | |||
+ | |||
+ | <html> | ||
+ | <style> | ||
+ | |||
+ | #tabletu { | ||
+ | background-color: transparent; | ||
+ | border-collapse: collapse; | ||
+ | width:80%; | ||
+ | } | ||
+ | |||
+ | #tabletu td, th { | ||
+ | border: 1px solid #000000; | ||
+ | padding: 8px; | ||
+ | } | ||
+ | |||
+ | #tabletu th { | ||
+ | padding: 8px; | ||
+ | text-align: left; | ||
+ | border: 1px solid #000000; | ||
+ | background-color: rgba(0,110,167,1); | ||
+ | color: white; | ||
+ | } | ||
+ | |||
+ | </style> | ||
+ | |||
+ | <body> | ||
+ | <b>Table 1:</b> Overview of different level in MoClo | ||
+ | <table id="tabletu"> | ||
+ | <tr> | ||
+ | <th>Level | ||
+ | </th> | ||
+ | <th>Basic/Composite | ||
+ | </th> | ||
+ | <th> | ||
+ | Type</th> | ||
+ | <th>Enzyme</th> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | Level 0 | ||
+ | </td> | ||
+ | <td>Basic</td> | ||
+ | <td>Promoters, 5’ UTR, CDS and terminators</td> | ||
+ | <td>BpiI</td> | ||
+ | |||
+ | </tr> | ||
+ | <tr> <td>Level 1</td> | ||
+ | <td>Composite</td> | ||
+ | <td>Transcriptional units</td> | ||
+ | <td>BsaI</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | Level 2/M/P</td> | ||
+ | <td>Composite</td> | ||
+ | <td>Multiple transcriptional units</td> | ||
+ | <td>BpiI</td> | ||
+ | </tr> | ||
+ | |||
+ | |||
+ | </table> | ||
+ | |||
+ | |||
+ | </body> | ||
+ | </html> | ||
+ | |||
+ | For synthesizing basic parts, the part of interest should be flanked by a <span style="color:limegreen">BpiI site</span> and its <span style="color:dodgerblue">specific type overhang</span>. These parts can then be cloned into the respective level 0 MoClo parts. For level 1, where individual transcriptional units are cloned, the overhangs come from the backbone you choose. The restriction sites for level 1 are BsaI. However, any type IIS restriction enzyme could be used. | ||
+ | |||
+ | |||
+ | |||
+ | <html> | ||
+ | <style> | ||
+ | |||
+ | #tabletu { | ||
+ | background-color: transparent; | ||
+ | border-collapse: collapse; | ||
+ | width:100%; | ||
+ | } | ||
+ | |||
+ | #tabletu td, th { | ||
+ | border: 1px solid #000000; | ||
+ | padding: 8px; | ||
+ | } | ||
+ | |||
+ | #tabletu th { | ||
+ | padding: 8px; | ||
+ | text-align: left; | ||
+ | border: 1px solid #000000; | ||
+ | background-color: rgba(0,110,167,1); | ||
+ | color: white; | ||
+ | } | ||
+ | |||
+ | |||
+ | </style> | ||
+ | |||
+ | <body> | ||
+ | <b>Table 2:</b> Type specific overhangs and backbones for MoClo. Green indicates the restriction enzyme recognition site. Blue indicates the specific overhangs for the basic parts | ||
+ | <table id="tabletu"> | ||
+ | <tr> | ||
+ | <th>Basic Part | ||
+ | </th> | ||
+ | <th>Sequence 5' End | ||
+ | </th> | ||
+ | <th> | ||
+ | Sequence 3' End</th> | ||
+ | <th>Level 0 backbone</th> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | Promoter | ||
+ | </td> | ||
+ | <td>NNNN <span style="color:limegreen">GAAGAC</span> NN <span style="color:dodgerblue">GGAG</span></td> | ||
+ | <td><span style="color:dodgerblue">TACT</span> NN <span style="color:limegreen">GTCTTC</span> NNNN</td> | ||
+ | <td>pICH41233</td> | ||
+ | |||
+ | </tr> | ||
+ | <tr> <td>5’ UTR</td> | ||
+ | <td>NNNN <span style="color:limegreen">GAAGAC</span> NN <span style="color:dodgerblue">TACT</span></td> | ||
+ | <td><span style="color:dodgerblue">AATG</span> NN <span style="color:limegreen">GTCTTC</span> NNNN</td> | ||
+ | <td>pICH41246</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | CDS</td> | ||
+ | <td>NNNN <span style="color:limegreen">GAAGAC</span> NN <span style="color:dodgerblue">AATG</span></td> | ||
+ | <td><span style="color:dodgerblue">GCTT</span> NN <span style="color:limegreen">GTCTTC</span> NNNN</td> | ||
+ | <td>pICH41308</td> | ||
+ | </tr> | ||
+ | <tr> | ||
+ | <td> | ||
+ | Terminator</td> | ||
+ | <td>NNNN <span style="color:limegreen">GAAGAC</span> NN <span style="color:dodgerblue">GCTT</span></td> | ||
+ | <td><span style="color:dodgerblue">CGCT</span> NN <span style="color:limegreen">GTCTTC</span> NNNN</td> | ||
+ | <td>pICH41276</td> | ||
+ | </tr> | ||
+ | |||
+ | |||
+ | </table> | ||
+ | |||
+ | |||
+ | </body> | ||
+ | </html> | ||
+ | |||
+ | ===References=== | ||
+ | <html> | ||
+ | <ul> | ||
+ | <li> | ||
+ | <a id="Salas1994" href="https://www.pnas.org/content/91/25/12198" target="_blank"> | ||
+ | Blanco, L., Lázaro, J. M., De Vega, M., Bonnin, A., & Salas, M. (1994). Terminal protein-primed DNA amplification.<i>Proceedings of the National Academy of Sciences of the United States of America</I>.</a> | ||
+ | </li> | ||
+ | <li> | ||
+ | <a id="Blanco1988" href="https://www.ncbi.nlm.nih.gov/pubmed/2498321" target="_blank"> | ||
+ | Blanco, L., Bernads, A., Lharo, J. M., Martins, G., & Garmendia, C. (1989). Highly Efficient DNA Synthesis by the Phage 429 DNA Polymerase.</a> | ||
+ | </li> | ||
+ | </ul> | ||
+ | |||
+ | </html> | ||
− | |||
− | |||
− | |||
Latest revision as of 06:22, 14 December 2019
Φ29 Terminal Protein (TP/p3)
Terminal Protein of the Φ29 bacteriophage
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12INCOMPATIBLE WITH RFC[12]Illegal NheI site found at 190
- 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 510
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
The part has been confirmed by sequencing and there are no mutations.
Usage and Biology
The Φ29 replication mechanism involves replication of a protein-primed based replication linear DNA. Protein primed replication, unlike the conventional DNA or RNA primed mechanism, does not depend on specific sequences of DNA/RNA which simplifies the design of replication systems. The Φ29 replication can be established by using four simple proteins: Φ29 DNA polymerase (DNAP/p2), terminal protein (TP/p3), single stranded binding protein (SSB/p5) and double stranded binding protein (DSB/p6). The replication process begins by binding of the Φ29 DNA polymerase and terminal protein complex at the origins of replication (OriL and OriR), which flank the protein-primed linear plasmid (Salas et al., 1994). The double stranded DNA binding proteins aid in the process of replication and bind more intensely at the origins of replication (OriL and OriR), destabilizing the region and facilitating strand displacement. Single stranded binding proteins bind to the displaced DNA strand preventing strand switching of the DNA polymerase and protecting the linear plasmid from host nucleases (Salas et al., 1994). The replication mechanism is depicted in Figure 1. If you want to read more about this mechanism, you can take a look at our Design page!
The Φ29 replication system is promising in many ways:
- The Φ29 DNA polymerase has the highest processivity of all known single subunit DNA polymerases (Blanco et al., 1989), and can be used for whole genome amplification.
- The Φ29 machinery along with cell-free expression systems can be used to establish the three dogmas of biology in vitro, setting the basis for artificial cell development.
- The existing DNA-protein covalent bonds offer many possibilities to engineer the terminal proteins with functional peptide sequences.
- We envision that the unique configuration of the double-stranded, protein-capped linear replicon will be a basis for many new engineered protein-DNA complexes.
- Orthogonal replication enables not only replication independent from the host, but also the ability to engineer the orthogonal DNA polymerase’s fidelity without introducing mutations in the cell’s genome which makes in vivo directed evolution a possibility.
Characterization
For expressing our phi29 TP we used PUREfrex 2.0. This is an E. coli based cell-free protein synthesis system and it contains all the elements to make in vitro translation-transcription possible. A 10-μL reaction consists of 5 μL feeding buffer, 0.5 μL enzyme solution, 1 μL ribosome solution, 5 nM DNA and RNAse-free milliQ for filling up the volume. For fluorescent labeling, 0.5 μL of BODIPY-Lys-tRNALys (FluoroTectTM GreenLys, Promega) was added, this binds to the translation products at the lysine residues sites.The proteins were identified by mass spectrometry. From the 10-μL reaction, 2 μL was analyzed by the mass spectrometer.
Mass Spectrometer
Mass spectrometry was used to confirm the identity of the proteins. The mass spectrometer looks for the mass of unique peptide sequences, and their elution time. For TP these unique peptide sequences are: IAEIER, LVDEK and ILSYLEQYR. Data was normalized to the presence of the elongation factor EF-TU, which can be found in the same concentration in all PURE system reactions. The optimized parameters and raw data for the mass spectrometry method can be found here and here.
The intensity of the mass spectrographs shown in Figure 2 only reflect the occurrence of a given sequence in the sample. The successful expression of DNAP from our construct was confirmed by mass spectrometry as reported by figure 2. In conclusion, the results were positive and the identity of the proteins could be further by mass spectrometry.
Toxicity
Our Sci-Phi 29 tool is based on four components of the Φ29 bacteriophage: DNAP, TP, p5 and p6. However, overexpression of these proteins are toxic for the cell. In order to determine the optimal expression levels of the proteins in live cells, we carried out viability assays in E. coli BL21(DE3) pLysS. The results are shown in the graphs below.
Strain Construction
The DNA sequence of the part was synthesized by IDT with flanking BpiI sites and respective MoClo compatible coding sequence overhangs. The part was then cloned in a level 0 MoClo backbone pICH41308 and the sequence was confirmed by sequencing. The cloning protocol can be found in the MoClo section below.
Modular Cloning
Modular Cloning (MoClo) is a system which allows for efficient one pot assembly of multiple DNA fragments. The MoClo system consists of Type IIS restriction enzymes that cleave DNA 4 to 8 base pairs away from the recognition sites. Cleavage outside of the recognition site allows for customization of the overhangs generated. The MoClo system is hierarchical. First, basic parts (promoters, UTRs, CDS and terminators) are assembled in level 0 plasmids in the kit. In a single reaction, the individual parts can be assembled into vectors containing transcriptional units (level 1). Furthermore, MoClo allows for directional assembly of multiple transcriptional units. Successful assembly of constructs using MoClo can be confirmed by visual readouts (blue/white or red/white screening). For the protocol, you can find it here.
Note: The basic parts sequences of the Sci-Phi 29 collection in the registry contain only the part sequence and therefore contain no overhangs or restriction sites. For synthesizing MoClo compatible parts, refer to table 2.
Level | Basic/Composite | Type | Enzyme |
---|---|---|---|
Level 0 | Basic | Promoters, 5’ UTR, CDS and terminators | BpiI |
Level 1 | Composite | Transcriptional units | BsaI |
Level 2/M/P | Composite | Multiple transcriptional units | BpiI |
For synthesizing basic parts, the part of interest should be flanked by a BpiI site and its specific type overhang. These parts can then be cloned into the respective level 0 MoClo parts. For level 1, where individual transcriptional units are cloned, the overhangs come from the backbone you choose. The restriction sites for level 1 are BsaI. However, any type IIS restriction enzyme could be used.
Table 2: Type specific overhangs and backbones for MoClo. Green indicates the restriction enzyme recognition site. Blue indicates the specific overhangs for the basic parts
Basic Part | Sequence 5' End | Sequence 3' End | Level 0 backbone |
---|---|---|---|
Promoter | NNNN GAAGAC NN GGAG | TACT NN GTCTTC NNNN | pICH41233 |
5’ UTR | NNNN GAAGAC NN TACT | AATG NN GTCTTC NNNN | pICH41246 |
CDS | NNNN GAAGAC NN AATG | GCTT NN GTCTTC NNNN | pICH41308 |
Terminator | NNNN GAAGAC NN GCTT | CGCT NN GTCTTC NNNN | pICH41276 |
References
- Blanco, L., Lázaro, J. M., De Vega, M., Bonnin, A., & Salas, M. (1994). Terminal protein-primed DNA amplification.Proceedings of the National Academy of Sciences of the United States of America.
- Blanco, L., Bernads, A., Lharo, J. M., Martins, G., & Garmendia, C. (1989). Highly Efficient DNA Synthesis by the Phage 429 DNA Polymerase.